Key result
A discriminant model incorporating patient characteristics and echocardiographic findings of increased left ventricular mass index with modest septal thickening and papillary muscle hypertrophy identified ATTRwt-CA with an AUC of 0.922.
Why the study?
Wild-type transthyretin cardiac amyloidosis occurs frequently in older patients with left ventricular hypertrophy, but detecting it via echocardiography remains challenging.
Cohort (n=311)
Yes
Effect estimate: AUC 0.922 (95% CI 0.890-0.954)
Specific echocardiographic features, including extensive left ventricular mass index with modest septal thickening and enlarged papillary muscles, can accurately discriminate wild-type transthyretin cardiac amyloidosis from other subtypes.
BACKGROUND: Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) occurs at a high prevalence in older patients with left ventricular (LV) hypertrophy. However, detecting ATTRwt-CA using echocardiography is challenging. OBJECTIVES: This study identified echocardiographic findings characterizing ATTRwt-CA compared with monoclonal immunoglobulin light chain cardiac amyloidosis (CA) and hereditary transthyretin CA. METHODS: We conducted a multicenter, retrospective study on the echocardiographic findings characterizing ATTRwt-CA. J-CASE (Japan Cardiac Amyloidosis Survey of typical Echocardiographic findings) analyzed echocardiographic data in 311 patients with histologically proven amyloid deposition in the myocardium and diagnosis of transthyretin CA or monoclonal immunoglobulin light chain CA. RESULTS: Among the cohort, 172 patients (55.3%) were diagnosed with ATTRwt-CA. A multiple discriminant analysis revealed that LV hypertrophy with a more extensive LV mass index but relatively modest interventricular septum thickening and enlargement of maximal papillary muscle diameter were significant echocardiographic findings characterizing ATTRwt-CA. In addition to the patient backgrounds such as advanced age, male sex, concomitant diabetes mellitus, hyperlipidemia, carpal tunnel syndrome, and paroxysmal atrial fibrillation, the discriminant model, including these echocardiographic findings showed significant discriminant power of ATTRwt-CA from the other subtypes (83.8% accuracy with 86.0% positive predictive value and 81.4% negative predictive value, when the sensitivity and specificity are at their maximum values of the model). CONCLUSIONS: In the J-CASE data set, LV hypertrophy with a more extensive LV mass index but relatively modest interventricular septum thickening and enlargement of papillary muscle diameter significantly characterized ATTRwt-CA. These findings may lead to more accurate screening echocardiography for diagnosing ATTRwt-CA and motivate the subsequent comprehensive clinical diagnostic process, including multimodality imaging.
No takes yet. Share an insight, caveat, or question.
Kitada et al. (2025) conducted a cohort in Cardiac amyloidosis (n=311). Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) vs. Monoclonal immunoglobulin light chain CA (AL-CA) and hereditary/variant transthyretin CA (ATTRv-CA) was evaluated on Discriminant model accuracy for identifying ATTRwt-CA (AUC 0.922, 95% CI 0.890-0.954). A discriminant model incorporating patient characteristics and echocardiographic findings of increased left ventricular mass index with modest septal thickening and papillary muscle hypertrophy identified ATTRwt-CA with an AUC of 0.922.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: